Clinical and genomic correlates of imatinib response in melanomas with KIT alterations-Reference-Cited by-同舟云学术

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations

Published:2022-08-23 Issue:9 Volume:127 Page:1726-1732
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Jung Seungyeon^ORCID,Armstrong Emma,Wei Alexander Z.,Ye Fei,Lee Aaron,Carlino Matteo S.,Sullivan Ryan J.,Carvajal Richard D.,Shoushtari Alexander N.^ORCID,Johnson Douglas B.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-01942-z.pdf

Reference23 articles.

1. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–6.

2. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29:2327–34.

3. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. J Am Med Assoc. 2011;305:3182–90.

4. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31:3182–90

5. Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is primary breast melanoma a true pathological entity? The argument against it;Heliyon;2024-09

2. Advances in Melanoma: From Genetic Insights to Therapeutic Innovations;Biomedicines;2024-08-14

3. Genomic and clinical characterization of a familial GIST kindred intolerant to imatinib;npj Genomic Medicine;2024-03-27

4. Multidisciplinary approach and treatment of acral and mucosal melanoma;Frontiers in Oncology;2024-02-26

5. Pharmaco‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G;PROTEOMICS;2024-02-09